This capital increase will enable the Company to have adequate financial capacity adapted to its growth strategy and improve its worldwide unique technological platform.
BioProtein Technologies intends to become the undisputed leader in the production of recombinant proteins in the milk of transgenic rabbits and is currently working on the development of an innovative biological drug in the prevention or treatment of the septic shock.
Jouy-en-Josas, France – April 28, 2010 – BioProtein Technologies, the biotechnology company specialized in the production of therapeutic proteins in the milk of transgenic rabbits, announced today the reinforcement of its capital base with a 0.52 Million Euros raised from its historical shareholders.
In order to achieve this fundraise, BioProtein was able to lean on the trust and support of its original shareholders. The Company has raised nearly 11Million Euros since its foundation in 1998.
Following on from the success in the production of recombinant proteins in part for internal projects or programs conducted in collaboration with various pharmaceutical and biotechnology companies, BioProtein intends to develop its growth and expand its commercial offer.
Alexandre Fouassier, COO of BioProtein Technologies, declared: “We are delighted to have completed this capital increase with our shareholders who maintain their historical support and confidence in the development of BioProtein, allowing us to improve our growth. With this strengthening of our capital, we will continue to develop our technology platform and reinforce our expertise in the fields of molecular biology and embryology. We are currently developing optimized transgenic strains enabling us to produce more efficiently complex glycosylated protein or recombinant vaccines in the milk of transgenic rabbits. BioProtein develops genetically improved strains for the quality of proteins produced (especially glycosylation) and also strains producing less natural milk proteins, thus facilitating the purification steps of a therapeutic protein of interest from the milk.
We are also working on the development of a proprietary therapeutic protein in the prevention and treatment of the septic shock. This phenomenon also called endotoxic shock consists in a severe multiorgan failure triggered by an inflammatory reaction of the body due to a bacterial infection. It is the leading cause of death in intensive care units with a high morbidity rate of 25 to 40%. The therapeutic options are very limited in this indication, while the number of cases of septic shock has amplified in recent decades, mainly due to the increased number of invasive medical interventions on ever more aged patients.
About BioProtein Technologies (BPT)
BioProtein Technologies is the world leader in the production of recombinant proteins in the milk of transgenic rabbits. The Company’s unique contract manufacturing capabilities have been designed to meet the increasing demands of the pharmaceutical and the biotechnology industries for therapeutic protein production. Rabbits offer great advantages in terms of scale-up and time-to-market and can produce up to 10-15 liters of milk per year. From the annual production of few hundred rabbits, several kilograms of protein can be isolated and purified to a very high quality.
BioProtein Technologies has strong expertise through the entire manufacturing process from genes or cDNA expression to animal production and milking. The Company has produced complex and difficult-to-express proteins, including monoclonal antibodies, plasma proteins, hormones and vaccinating antigens, all of which demonstrates BioProtein Technologies’ ability to fulfill the most rigorous specifications in protein production.
For more information please visit: www.bioprotein.com
